Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2011-07-12
2011-07-12
Duffy, Patricia A (Department: 1612)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C424S810000
Reexamination Certificate
active
07977376
ABSTRACT:
Topical formulations of olopatadine for treatment of allergic or inflammatory disorders of the nose are disclosed. The aqueous formulations contain approximately 0.6% (w/v) of olopatadine.
REFERENCES:
patent: 4407791 (1983-10-01), Stark
patent: 4749700 (1988-06-01), Wenig
patent: 4778596 (1988-10-01), Linder et al.
patent: 4871865 (1989-10-01), Lever, Jr. et al.
patent: 4923892 (1990-05-01), Lever, Jr. et al.
patent: 5116863 (1992-05-01), Oshima et al.
patent: 5164194 (1992-11-01), Hettche
patent: 5443833 (1995-08-01), Clark et al.
patent: 5478565 (1995-12-01), Geria
patent: 5482706 (1996-01-01), Igari et al.
patent: 5641805 (1997-06-01), Hayakawa et al.
patent: 6054462 (2000-04-01), François et al.
patent: 6146622 (2000-11-01), Castillo et al.
patent: 6174914 (2001-01-01), Yanni et al.
patent: 6207684 (2001-03-01), Aberg
patent: 6316483 (2001-11-01), Hasiwanter et al.
patent: 6333044 (2001-12-01), Santus et al.
patent: 6995186 (2006-02-01), Castillo et al.
patent: 2001/0056093 (2001-12-01), Yanni
patent: 2006/0110328 (2006-05-01), Cagle et al.
patent: 0 048 023 (1982-03-01), None
patent: 0 214 779 (1987-03-01), None
patent: 0 235 796 (1987-09-01), None
patent: 61926 (1995-03-01), None
patent: WO 00/03705 (2000-01-01), None
patent: WO 01/21209 (2001-03-01), None
patent: WO 01/21210 (2001-03-01), None
patent: WO 01/35963 (2001-05-01), None
patent: WO 01/54687 (2001-08-01), None
patent: WO 02/30395 (2002-04-01), None
patent: WO 03/002093 (2003-01-01), None
patent: WO 03002093 (2003-01-01), None
patent: WO 2004/043470 (2004-05-01), None
PH Ratner, FC Hampel, NJ Amar, JH van Bevel, D Mohar, BF Marple, PS Roland, GM Wall, MJ Brubaker, M Drake, D Turner, LH Silver. Safety and Efficacy of Olopatadine Hydrochloride Nasal Spray for the Treatment of Seasonal Allergic Rhinitis to Mountain Cedar. Annals Allergy Asthma Immunol. 2005. vol. 95, pp. 474-479.
SM Berge, LD Bighley, DC Monkhouse. “Pharmaceutical Salts.” Journal of Pharmaceutical Science, vol. 66, No. 1, pp. 1-19, Jan. 1977.
Church, “Is Inhibition of Mast Cell Mediator Release Relevant to the Clinical Activity of Anti-allergic Drugs?,”Agents and Actions, vol. 18, ¾, pp. 288-293 (1986).
Clegg et al., “Histamine Secretion from Human Skin Slices Induced by Anti-IgE and Artificial Secretagogues and the Effects of Sodium Cromoglycate and Salbutanol,”Clin. Allergy, vol. 15, pp. 321-328 (1985).
Hamilton et al., “Comarison of a New Antihistaminic and Antiallergic Compound KW 46790 with Terfenadine and Placebo on Skin and Nasal Provocation in Atopic Individuals,”Clinical and Experimental Allergy, vol. 24, pp. 955-959 91994).
Ikeda et al., “Effects of Oxatomide and KW-4679 on Acetylcholine-Induced Responses in the Isolated Acini of Guinea Pig Nasal Glands,”Int. Arch. Allergy Immunol., vol. 106, p. 157-162 (1995).
Irani et al., “Mast Cell Heterogeneity,”Clinical and Experimental Allergy, vol. 19, pp. 143-155 (1989).
Kamei et al., “Effects of Certain Antiallergic Drugs on Experimental Conjunctivitis in Guinea Pigs,”Atarashii Ganka, vol. 11(4), p. 603-605 (1994) (abstract only).
Kamei et al., “Effect of (Z)-11-[3-(Dimethylamino) propylidene]-6,11-dihydrodibenz[b,e]oxepin-2-acetic Acid Hydrochloride on Experimental Allergic Conjunctivitis and Rhinitis in Rats and Guinea Pigs,”Arzneimittelforschung, vol. 45(9), p. 1005-1008 (1995).
Ohshima et al., “Synthesis and Antiallergic Activity of 11-(Am inoalkylidene)-6,11,dihydrodibenz[b,e]oxepin Derivatives,”J. Medicinal Chemistry, vol. 35(11), p. 2074-2084 (1992).
Pearce et al., “Effect of Disodium Cromoglycate on Antigen Evoked Histamine Release in Human Skin,”Clinical Exp. Immunol., vol. 17, pp. 437-440 (1974).
Pujara et al., “Effects of formulation variables on nasal epithelial cell integrity: Biochemical evaluations,”International J. of Pharmaceutics, vol. 114, pp. 197-203 (1995).
Sharif et al., “Characterization of the Ocular Antiallergic and Antihistaminic Effects of Olopatadine (AL-4943A), a Novel Drug for Treating Ocular Allergic Diseases,”J. of Pharmacology and Experimental Therapeuticsl, vol. 278(3), p. 1252-1261 (1996).
Sharif et al., “Olopatadine (AL-4943A): Pharmacological Profile of a Novel Anti-histaminic/Anti-allergic Drug for Use in Allergic Conjunctivitis,”Investigative Ophthalmology&Visual Science, vol. 37(3), p. 1027 (1996) (abstract only).
Siraganian, “An Automated Continuous Flow System for the Extraction and Fluorometric Analysis of Histamine,”Anal. Biochem., vol. 57, pp. 383-394 (1974).
Spitalny et al., “Olopatadine Ophthalmic Solution Decreases Itching and Redness Associated with Allergic Conjunctivitis,”Investigative Ophthalmology&Visual Science, vol. 37(3), p. 593 (1996) (abstract only).
“The Lung,”Scientific Foundation, Raven Press, Ltd., New York, Ch. 3.4.11 (1991).
Yanni et al., “The In Vitro and In Vivo Ocular Pharmacology of Olopatadine (AL-4943A), An Effective Anti-allergic/Anti-histaminic Agent,”Investigative Ophthalmology&Visual Science, vol. 37(3), p. 1028 (1996) (abstract only).
Zhang et al., “Optically Active Analogues of Ebastine: Synthesis and Effect of Chirality on Their Antihistaminic and Antimuscarinic Activity,”Chirality, vol. 6(8), p. 631-641 (1994).
Astelin® Nasal Spray Product Insert.
Hamilton et al., “Comarison of a New Antihistaminic and Antiallergic Compound KW 46790 with Terfenadine and Placebo on Skin and Nasal Provocation in Atopic Individuals,”Clinical and Experimental Allergy, vol. 24, pp. 955-959, (1994).
Chowhan Masood A.
Han Wesley Wehsin
Jani Rajni
Singh Onkar N.
Wall G. Michael
Duffy Patricia A
Novartis AG
Ryan Patrick M.
Shomer Isaac
LandOfFree
Olopatadine formulations for topical nasal administration does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Olopatadine formulations for topical nasal administration, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Olopatadine formulations for topical nasal administration will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2729637